HomeCompareGTVI vs ABBV

GTVI vs ABBV: Dividend Comparison 2026

GTVI yields 2735.98% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GTVI wins by $189316788485.81M in total portfolio value
10 years
GTVI
GTVI
● Live price
2735.98%
Share price
$0.07
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$189316788485.92M
Annual income
$176,618,059,162,830,100.00
Full GTVI calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — GTVI vs ABBV

📍 GTVI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGTVIABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GTVI + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GTVI pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GTVI
Annual income on $10K today (after 15% tax)
$232,558.14/yr
After 10yr DRIP, annual income (after tax)
$150,125,350,288,405,600.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, GTVI beats the other by $150,125,350,288,384,540.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GTVI + ABBV for your $10,000?

GTVI: 50%ABBV: 50%
100% ABBV50/50100% GTVI
Portfolio after 10yr
$94658394243.01M
Annual income
$88,309,029,581,427,440.00/yr
Blended yield
93.29%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

GTVI
No analyst data
Altman Z
-352.5
Piotroski
2/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GTVI buys
0
ABBV buys
0
No recent congressional trades found for GTVI or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGTVIABBV
Forward yield2735.98%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$189316788485.92M$102.3K
Annual income after 10y$176,618,059,162,830,100.00$24,771.77
Total dividends collected$188434297429.38M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: GTVI vs ABBV ($10,000, DRIP)

YearGTVI PortfolioGTVI Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$284,298$273,597.81$11,550$430.00+$272.7KGTVI
2$7,573,662$7,269,463.45$13,472$627.96+$7.56MGTVI
3$189,092,322$180,988,503.35$15,906$926.08+$189.08MGTVI
4$4,425,465,879$4,223,137,095.00$19,071$1,382.55+$4425.45MGTVI
5$97,106,431,266$92,371,182,774.71$23,302$2,095.81+$97106.41MGTVI
6$1,998,173,195,581$1,894,269,314,127.15$29,150$3,237.93+$1998173.17MGTVI
7$38,566,695,680,810$36,428,650,361,538.01$37,536$5,121.41+$38566695.64MGTVI
8$698,377,165,488,344$657,110,801,109,877.20$50,079$8,338.38+$698377165.44MGTVI
9$11,867,971,329,987,452$11,120,707,762,914,926.00$69,753$14,065.80+$11867971329.92MGTVI
10$189,316,788,485,916,700$176,618,059,162,830,100.00$102,337$24,771.77+$189316788485.81MGTVI

GTVI vs ABBV: Complete Analysis 2026

GTVIStock

Joway Health Industries Group Inc. does not have significant operations. Previously, it was engaged in the manufacture and sale of tourmaline-related healthcare products. The company is based in Las Vegas, Nevada. Joway Health Industries Group Inc. is a subsidiary of JHP Holdings, Inc.

Full GTVI Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this GTVI vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GTVI vs SCHDGTVI vs JEPIGTVI vs OGTVI vs KOGTVI vs MAINGTVI vs JNJGTVI vs MRKGTVI vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.